Ayurcann Holdings Corp. · OTC:AYURF
Ayurcann — Investor Presentation (December 2021)
24 slides from Ayurcann's investor presentation, December 2021
Slide 1: Ayurcann Holdings Corp. Investor Presentation
Ayurcann Holdings Corp. (CSE: AYUR) Investor Presentation December 2021 Toll Processing & White Label Manufacturing Solutions For Canadian Licensed Producers
Slide 2: Ayurcann at a Glance
Ayurcann at a Glance 3 Consecutive Q’s Of Positive EBIDTA And Cash Flow Canada - Wide 6 Recreational Distribution Brands 3 Medicinal Brands Very Low Debt Opex Free = Massive Operating Leverage 87 National Category High Gross Listings Margins Asset Light = Outstanding Low Capex 2 Investor Presentatio
Slide 3: Market Opportunity
Market Opportunity Rapidly growing Cannabis 2.0 market segment CANADIAN CANNABIS MARKET * CANNABIS 2.0 SEGMENT SALES GROWTH** Capsules Tinctures Capsules Tinctures & Sublinguals & Sublinguals $10.1B 10% Vape Pens 6% Vape Pens 2025 3.9% 18% Edibles Edibles 1% 9% Topicals Topicals 0% ** 1% ~3x $3.1B 2
Slide 4: Market Opportunity: Market Moves Away From Vertical Integration
Market Opportunity As the cannabis market matures, it moves away from vertical integration As the industry matures, companies specialize and develop competitive advantages in certain segments Service providers develop expertise of the value chain (cultivation, and utilize economies of scale manufact
Slide 5: The Value Chain
The Value Chain Me dic a l Branding Recrea tion Ayurcann is a leading al post harvest solution provider Packaging with a focus on providing and creating custom processes Fulfillment and pharma grade products d for the adult use and medical Manufacturing nn e cannabis Industry in Canada. ca vid Purif
Slide 6: Milestones & Action Plan
Milestones & Action Plan Unparalleled execution & capital deployment efficiency 2018 2019 2020 2021 Q1 - Q2. Q3 - Q4. Q1. Q2 - Q4. • Standard Processing • Over $2,500,000 • Over $2,500,000 • Over $7,500,000 in revenue • Submitted Health • Health Canada License Granted in Revenue* in revenue • Launch
Slide 7: 2021 Milestones
2021 Milestones Commences Trading on The CSE - April 8 Announces Oversubscribed Private Placement - April 19 Enters into agreements with Cannmart and Patient Choice - April 29 Forms Powerhouse Advisory Board With Leading Cannabis and CPG Executives - May 6 Signs Partnership Agreement with Kindred Pa
Slide 8: Key Success Factors
Key Success Factors Simple formula: top services and products, priced competitively (yet profitably…) SERVICES TO LPS MEDICAL LINE OPERATIONAL AND AND BRANDS: OF PRODUCTS FINANCIAL EXCELLENCE • Leveraging efficient technology • Sales license received • $7.65mm in revenue 2021 and infrastructure Jan
Slide 9: Our Offering To LPs and Brands
Our Offering To LPs and Brands EXTRACTION & BULK OIL WHITE LABEL REFINEMENT SALES MANUFACTURING 9 Investor Presentation. © 2021 Ayurcann Inc. All rights reserved. Confidential for discussion purposes only.
Slide 10: Extraction & Refinement
Extraction & Refinement • Produced over 2,000,000 grams of cannabis extract • Ethanol extraction specialists • Low cost and high volume production capabilities • Fast and flexible production 9,308 kg Biomass extracted in 2021 0 5% +2 4,530 kg 6% 2,430 kg +18 9% 380 kg +63 Q1 Q2 Q3 Q4 10 Investor Pre
Slide 11: Bulk Oil Sales
Bulk Oil Sales • 1,250,000 grams of cannabis extract was sold* • Secured monthly biomass supply to ensure high throughput • Monthly inventory availability of over 300kg of distillate • Inventory to supply leading licensed producers to support Edibles, Topicals & Vape Production • Quality supply CBD
Slide 12: White Label Manufacturing
White Label Manufacturing Current manufacturing capacity of 3 million units. BC AB SK MB ON NB 12 Investor Presentation. © 2021 Ayurcann Inc. All rights reserved. Confidential for discussion purposes only.
Slide 13: Medical Line of Products
Medical Line of Products Tincture Vape Pens Topicals 13 Investor Presentation. © 2021 Ayurcann Inc. All rights reserved. Confidential for discussion purposes only.
Slide 14: Brands: Strategic Partnerships with Industry Leaders
Brands Strategic Partnerships with Industry Leaders
Slide 15: Brands
Brands 15 Investor Presentation. © 2021 Ayurcann Inc. All rights reserved. Confidential for discussion purposes only.
Slide 16: Products
Products 16 Investor Presentation. © 2021 Ayurcann Inc. All rights reserved. Confidential for discussion purposes only.
Slide 17: Financial Highlights
Financial Highlights 2021 Fiscal Year end Jun 30 • REVENUE - $7.65mm Growth of 1,149% over fiscal year 2020 • Operating Income - $2,159,309, an increase of 440% over fiscal year 2020 • Gross margins of 60%. 2021 2022 Q1 2022 • REVENUE - $1.9mm Growth of 137% YoY • Gross margin of $931,000 increase o
Slide 18: Competitive Landscape
Competitive Landscape Attractive Valuation Relative to Peer Group Current Annual 200,000 kg 200,000 kg 300,000 kg 100,000 kg 425,000 kg Extraction Capacity Annual Extraction 300,000 kg 400,000 kg 575,000 kg 100,000 kg 425,000 kg Capitalization Capacity at Full Expansion Issued & Canadian Facility Gr
Slide 19: Management and Directors
Management and Directors Igal Sudman Roman Buzaker Jaspreet Bhatia, Phd Raj Virk, M.sc CEO and Co-founder, Director President, COO and Co-founder, Director Quality Control Manager Quality & Compliance Manager Mr. Sudman is a business development Mr. Buzaker is a corporate strategist Mrs. Bhatia is a
Slide 20: Directors
Directors Alison Gordon David Hackett Maor Shayit Director Director Director A veteran of the cannabis industry, Alison has Mr. Hackett brings more than 20 years of financial Mr. Shayit is a seasoned and ambitious operations worked in all verticals of this emerging market. and management leadership.
Slide 21: Advisory Board
Advisory Board Paul Haber James McMillan Mr. Haber is the Chairman and Managing Director of Summit Bancorp Inc., Jay McMillan is an accomplished corporate development and M&A executive a Toronto based merchant bank. Mr. Haber has been involved in corporate with a passion for product innovation. Leve
Slide 22: Advisory Board
Advisory Board Iris Bincovich Casey Hiltemann Mrs. Iris Bincovich is the CEO of Innocan Pharma Casey Hiltemann is the Founder and CEO of Budtenders and an experienced C-level executive in healthcare Associate, an inclusive network working towards and biotech, with a proven track record in taking can
Slide 23: Disclaimer
Disclaimer General right of action for rescission is exercisable not later than 180 days from the date on which payment is made for the securities. If a purchaser elects to exercise the right The information contained in this presentation has been prepared by Ayurcann Inc. (“Ayurcann”) in connection
Slide 24: Thank You!
Thank You! Contact Us Igal Sudman CEO and Co-founder 905.492.3322 IR@ayurcann.com
Ayurcann Holdings — Investor Presentation (December 2021) on 6ix